May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Comparison of Pimecrolimus 1%, 0.3% and 0.1% With Vehicle for the Treatment of Dry Eye in the Controlled Adverse Environment (CAE) Model
Author Affiliations & Notes
  • G.W. Ousler
    ORA, N. Andover, MA
  • R. Haque
    Novartis, E. Hanover, NJ
  • A. Weichselberger
    Novartis, Basel, Switzerland
  • N.C. Yannoulis
    Novartis, Basel, Switzerland
  • M.B. Abelson
    ORA, N. Andover, MA
    Schepens Eye Inst, Harvard Med School, Boston, MA
  • Footnotes
    Commercial Relationships  G.W. Ousler, None; R. Haque, Novartis Ophthalmics E; A. Weichselberger, Novartis Ophthalmics E; N.C. Yannoulis, Novartis Ophthalmics E; M.B. Abelson, Novartis Ophthalmics F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2031. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      G.W. Ousler, R. Haque, A. Weichselberger, N.C. Yannoulis, M.B. Abelson; Comparison of Pimecrolimus 1%, 0.3% and 0.1% With Vehicle for the Treatment of Dry Eye in the Controlled Adverse Environment (CAE) Model . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2031.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To compare safety & efficacy of pimecrolimus 1%,0.3% and 0.1% ophthalmic suspensions with vehicle for treatingdry eye in the CAE model. Randomized, double–masked,parallel group, 16–week, single–center study. Dryeye patients entered a 4–week run–in period withvehicle treatment and underwent screening in the CAE, an environmentallyregulated room that standardizes humidity, temperature, airflow,and visual tasking. Subjects with worsened dry eye symptoms& corneal staining post CAE were randomized to dose BIDwith pimecrolimus or vehicle for 12 weeks. Follow–up CAEexposure and pre & post exposure exams occurred at weeks2, 4, 8, 12. 105 (1%: 26, 0.3%: 28, 0.1%: 24, vehicle:27) patients completed per protocol. Mean differences betweenpimecrolimus & vehicle for inferior corneal staining (0–4scale) after 12 weeks of treatment (primary efficacy variable– inferior corneal staining post CAE) are shown. Negativevalues favor pimecrolimus.



  *unstratified / baseline stratified CMH–test


Pimecrolimus 1% results suggested a treatment effect on cornealstaining pre & post CAE. The maximum effect of pimecrolimus1% occurred after 4 weeks and was sustained for the study. Similartrends were observed for sum corneal and conjunctival stainingpre & post CAE. All treatments were well tolerated. The data suggest a treatment effect for pimecrolimus in thereduction of corneal staining under both environmental and adverseconditions. Further evaluation of safety & efficacy of pimecrolimusfor dry eye therapy is warranted.


Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled • cornea: tears/tear film/dry eye 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.